ReviewCardiology research2018
Bioprosthetic Valve Thrombosis.
Review in Cardiology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- DOACs vs warfarin in AF with comorbid CKD or valvular disease: a systematic review and meta-analysis.Blood vessels, thrombosis & hemostasis · 2026Review
- A rare case of fulminant myocarditis complicated with thrombotic aorta occlusion and multiple thrombosis: a case report.Frontiers of medicine · 2025Article
- Minimally invasive aspiration of thrombi and masses in left-sided cardiac chambers: a comprehensive literature review.Frontiers in cardiovascular medicine · 2025Review
- Emergent Surgical Replacement of a Tendyne Prosthesis for Bioprosthetic Valve Thrombosis.JACC. Case reports · 2024Article
- Bioprosthetic mitral valve thrombosis: the role of cardiac CT in diagnosis and guiding the management.BMJ case reports · 2024Article
- Thromboaspiration of a left-sided bioprosthetic valve thrombosis by a mini-access: the Lausanne novel procedure.Frontiers in cardiovascular medicine · 2024Article
- Bioprosthetic Valve Deterioration: Accumulation of Circulating Proteins and Macrophages in the Valve Interstitium.JACC. Basic to translational science · 2023Article
- Performance of xenogeneic pulmonary visceral pleura as bioprosthetic heart valve cusps in swine.Frontiers in cardiovascular medicine · 2023Article
- Leaflet thrombosis in transcatheter aortic valve intervention: mechanisms, prevention, and treatment options.Frontiers in cardiovascular medicine · 2023Review
- Innovative IntraValvular Impedance Sensing Applied to Biological Heart Valve Prostheses: Design and In Vitro Evaluation.Sensors (Basel, Switzerland) · 2022Article
- Early Postoperative Immunothrombosis of Bioprosthetic Mitral Valve and Left Atrium: A Case Report.International journal of molecular sciences · 2022Article
- Bacterial infiltration and bioprosthetic valve failure: Emerging diagnostics for emerging therapies.The Journal of thoracic and cardiovascular surgery · 2020Article
- Reversal of Bioprosthetic Aortic Valve Thrombosis Using Rivaroxaban-A Case Report.Frontiers in cardiovascular medicine · 2020Article
- Thrombogenic and Inflammatory Reactions to Biomaterials in Medical Devices.Frontiers in bioengineering and biotechnology · 2020Review
- Oral Anticoagulant Therapy-When Art Meets Science.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degenerative valve disease is on the rise with greater than 100,000 valve operations performed in the US alone per year. The majority of those procedures employ tissue bioprostheses to avoid the attendant risk of anticoagulation, especially in the elderly. Though traditionally this approach has been considered a superior option to avoid anticoagulation, more recent analyses have demonstrated a significant incidence of previously unrecognized thrombosis associated with bioprosthetic valves, especially with the more recent advent of the transcatheter aortic valve replacement implantations. Bioprosthetic valve thrombosis is a major cause of either acute or indolent bioprosthetic valve degeneration, and often has an elusive presentation causing delayed recognition and treatment. The literature has extensively addressed the risks and benefits of anticoagulation following bioprosthetic valve replacement to prevent bioprosthetic valve thrombosis (BPVT), without conclusive evidence-based recommendations. The duration of anticoagulation following an episode of BPVT is unclear, and lifelong anticoagulation has been suggested. The increasing use of transcatheter aortic valve replacement as an alternative to surgical aortic valve replacement in various risk groups has introduced new challenges with regards to valve thrombosis, which have been poorly studied with regards to optimal treatment and prevention. The increasing use of valve-in-valve procedures is expected to bring on further uncharted challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.